Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) fell 6.9% during mid-day trading on Thursday . The stock traded as low as $6.62 and last traded at $6.64. 6,100,949 shares were traded during mid-day trading, a decline of 0% from the average session volume of 6,122,622 shares. The stock had previously closed at $7.13.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Tuesday, September 3rd. Finally, Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Down 7.6 %

The firm has a market cap of $1.89 billion, a PE ratio of -4.31 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $6.60 and a 200-day moving average price of $7.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. During the same quarter in the prior year, the firm earned ($0.43) EPS. The firm's revenue was up 147.6% compared to the same quarter last year. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher Gibson sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at $4,697,960.96. The trade was a 2.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,235 shares of company stock worth $895,538. Corporate insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. boosted its position in shares of Recursion Pharmaceuticals by 58.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company's stock valued at $127,000 after purchasing an additional 7,027 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $89,000. Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after acquiring an additional 656,003 shares during the period. Barclays PLC grew its position in shares of Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company's stock worth $4,596,000 after acquiring an additional 244,278 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $692,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.